CXCL9 influences effector T cell priming to cardiac allografts
CXCL9 influences effector T cell priming to cardiac allografts
批准号:
7544233
负责人:
Joshua M Rosenblum
金额:
$2.61万
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-09-01 至 2011-08-31
关键词:
AcuteAlloantigenAllogenicAllograftingAttenuatedBindingCD4 Positive T LymphocytesCD8B1 geneCXC chemokine receptor 3CXCL9 geneCXCR3 geneCardiacCardiovascular PathologyCellsChronicCommunitiesConditionDataDevelopmentEffector CellEnvironmentExposure toGenerationsGoalsGraft RejectionGraft SurvivalGraft ToleranceHeartHeart TransplantationHumanImmune responseInfiltrationInflammationInterferonsInvasiveLaboratoriesLeadLeukocytesLightMediatingMediator of activation proteinMethodsModelingMonokinesOrganOrgan TransplantationPersonal SatisfactionPhenotypePlayPreventionProductionPublishingRaceRecruitment ActivityRoleSiteSolidSourceSpleenT-Cell DevelopmentT-Cell ProliferationT-LymphocyteTestingTherapeuticTherapeutic InterventionTimeTransplantationUp-RegulationUpper armWorkbasechemokinechemokine receptorheart allograftimprovednovelpreventresponsetrafficking
中文摘要
描述(由申请人提供):尽管在侵入性和非侵入性治疗策略方面取得了进展,但心脏移植仍然是几种心血管疾病的最终治疗选择。尽管急性和慢性移植物排斥反应涉及体液和细胞免疫应答的全部,但移植界的主要目标是预防T细胞介导的急性排斥反应。目前的治疗旨在抑制或阻断由效应T细胞产生的干扰素(IFN)-γ,其最终导致免疫应答的其它臂的激活和随后的移植器官的排斥。本实验室最近的工作表明,趋化因子CXCL 9/Monokine Induced by IFN-?(MIG)在效应CD 4和CD 8 T细胞极化为IFN-γ中起作用。产生表型。我推测,在血管化心脏同种异体移植后,脾脏中的IFN-γ产生与引发期间T细胞上CXCR 3的上调相关,并且时机适合于将幼稚T细胞驱动为产生IFN-γ的效应子表型。此外,我相信尽管CD 8和CD 4 T细胞上表达CXCR 3,但MIG并不是促进效应子浸润到移植物中的关键或决定因素。这个建议概述了我将使用的方法来测试如何在同种异体反应性T细胞引发的网站上的IFN-γ的生产相关的幼稚T细胞的分化,导致一个主要的IFN-γ生产表型。特异性目标1将测试在引发位点处的TdR的来源和时间产生,因为它与T细胞增殖和效应表型的产生相关。Specific Aim 2将直接测试CXCR 3驱动效应细胞浸润到同种异体移植物中的需求,以及浸润效应物是否必须表达CXCR 3。更全面地了解T细胞如何在暴露于同种异体抗原后发育为产生IFN-v的表型以及它们如何迁移到移植的实体器官将有助于产生更合适和更有效的治疗干预靶点,以防止移植物排斥反应。
英文摘要
DESCRIPTION (provided by applicant): Despite advances in invasive and non-invasive therapeutic strategies, cardiac transplantation remains the final treatment option for several cardiovascular pathologies. Although acute and chronic graft rejection, involve a repertoire of humoral and cellular immunological responses, a predominant goal in the transplantation community is the prevention of T cell-mediated acute rejection. Current treatments aim at suppression or blockade of interferon (IFN)-v produced by effector T cells which ultimately lead to activation of the other arms of the immune response and subsequent rejection of the grafted organ. Recent work in our laboratory indicates that the chemokine CXCL9/Monokine Induced by IFN-? (MIG) plays a role in the polarization of effector CD4 and CD8 T cells to an IFN-?-producing phenotype. I hypothesize that, following vascularized cardiac allografting, MIG production in the spleen is correlated with upregulation of CXCR3 on T cells during priming, and that the timing is appropriate to drive naive T cells to an IFN-v-producing effector phenotype. Additionally, I believe that MIG is not a crucial or determinate factor in promoting effector infiltration into the graft despite expression of CXCR3 on CD8 and CD4 T cells. This proposal outlines the methods I will use to test how MIG production at the site of alloreactive T cell priming correlates to the differentiation of naive T cells resulting in a predominantly IFN-v-producing phenotype. Specific Aim 1 will test the source and temporal production of MIG at the site of priming as it correlates to T cell proliferation and generation of effector phenotype. Specific Aim 2 will directly test the requirement for MIG to drive effector cell infiltration into allografts, and whether infiltrating effectors must express CXCR3. A more complete understanding of how T cells develop to an IFN-v-producing phenotype following exposure to alloantigen and how they migrate to a transplanted solid organ will aid in generating more appropriate and more effective targets for therapeutic intervention in the race to prevent graft rejection.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CXCL9 influences effector T cell priming to cardiac allografts
-
批准号:7744039
-
项目类别:
-
资助金额:$4.62万
-
财政年份:2008
-
负责人:Joshua M Rosenblum
-
依托单位:
海外基金